Enzyme by Design — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Enzyme by Design is a private, preclinical-stage biotech leveraging rational structure-based enzyme engineering to develop safer oncology drugs. Its lead platform aims to eliminate toxic side activities from existing enzyme therapeutics, starting with a next-generation L-asparaginase for acute lymphoblastic leukemia and other hematological malignancies. The company is led by a scientifically strong founding team with deep expertise in structural biology and is supported by NIH/NCI grants, positioning it to address significant unmet needs in cancer care by improving therapeutic safety profiles.

OncologyHematological Malignancies

Technology Platform

Rational, structure-based enzyme engineering platform focused on modifying amino acids to eliminate off-target toxic activities while preserving therapeutic function, initially applied to L-asparaginase.

Opportunities

A safer L-asparaginase could capture significant market share in the established ALL treatment paradigm by becoming the new standard-of-care for a broader patient population, including those currently unable to tolerate existing drugs.

The underlying enzyme engineering platform also presents opportunities to improve other therapeutic enzymes where off-target activities limit their use, expanding into new indications.

Risk Factors

Key risks include the clinical failure to demonstrate reduced toxicity without loss of efficacy, competition from existing and next-generation asparaginase products, and the financial risk inherent to a small, pre-revenue biotech dependent on grants and future fundraising to advance through costly clinical trials.

Competitive Landscape

The company competes in the L-asparaginase market against approved products like Erwinase (Jazz Pharmaceuticals) and Oncaspar (Servier), as well as generic versions and PEGylated formulations. It also faces potential competition from other biotechs engineering improved enzymes or developing alternative therapies for ALL. Its differentiation is a pure focus on safety via precise protein engineering.

More companies in Biologics / Biosimilars →More companies in United States →